U.S., July 26 -- ClinicalTrials.gov registry received information related to the study (NCT07086755) titled 'Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung Injury' on July 18.
Brief Summary: The objective of this study is to assess the efficacy and safety of vadadustat for treating hospitalized patients with nonintubated Acute Respiratory Distress Syndrome (ARDS) secondary to pathogen-associated lung injury.
Study Start Date: Aug. 01
Study Type: INTERVENTIONAL
Condition:
Nonintubated Acute Respiratory Distress Syndrome (ARDS)
Pathogen-associated Lung Injury
Intervention:
DRUG: Vadadustat 900mg
Participants will receive 900mg vadadustat (as oral tablets) for 14 days or...